Hypertension in young adults with autosomal dominant polycystic kidney disease: a case for early screening?
- PMID: 37260997
- PMCID: PMC10229279
- DOI: 10.1093/ckj/sfad049
Hypertension in young adults with autosomal dominant polycystic kidney disease: a case for early screening?
Abstract
ADPKD is the most common hereditary kidney disease and a major cause of kidney failure world-wide. Significant kidney enlargement occurs decades preceding loss of kidney function. However, the earliest clinical manifestations of disease have been less well characterized in young adults, a typically healthy population who do not often seek routine medical care. In this study, Martinez and colleagues report a high prevalence of hypertension among young adults (18-30 years) enrolled in the Spanish ADPKD registry REPQRAD. Their findings confirm previous studies in children and young adults with ADPKD and make a strong case for earlier screening and intervention within this age group.
Keywords: ADPKD; age; ambulatory blood pressure monitoring; cardiovascular; hypertension.
© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.
Conflict of interest statement
M.A.C. reports having received consultancy fees and serving on the paediatric research steering committee for Otsuka Pharmaceuticals, Inc.
Figures
Comment in
- doi: 10.1093/ckj/sfac251
References
-
- Mekahli DG-W LG, Cadnapaphornchai MA, Greenbaum LGet al. Randomized, placebo-controlled, phase 3B trial of tolvaptan in the treatment of children and adolescents with autosomal dominant polycystic kidney disease (ADPKD): 1-year data. Nephrol Dial Transplant 2021;36:i89–90.
Publication types
LinkOut - more resources
Full Text Sources
